Kolexia
Villemin Maud Oncologie médicale
Villemin Maud
Oncologie médicale
Cabinet libéral
Caen, France
39 Activités
69 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de la tête et du cou Fragilité Phosphotransferases Cyclines Hormones Kinase-4 cycline-dépendante Kinases cyclines-dépendantes Trastuzumab

Collaborateurs

Voir plus
Da Silva Angelique
Da Silva Angelique
Centre François-Baclesse, Caen, France
Boscher Clemence
Boscher Clemence
Centre François-Baclesse, Caen, France
Cherifi François
Cherifi François
Centre François-Baclesse, Caen, France
Kammerer Emmanuel
Kammerer Emmanuel
Centre Eugène Marquis, Rennes, France

Industries

Voir plus
MSD
6 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2023
Ipsen
1 collaboration(s)
Dernière en 2023
Leo Pharma
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.
Frontiers in oncology   19 janvier 2023
Le centre contre le cancer Maurice Tubiana se refait une beauté ... - Actu
Actu FR   03 décembre 2022
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
BMC cancer   20 octobre 2022
Correction to: Impact of Early Supportive Care Assessment on treatment decision.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   22 juin 2022
104P HELENA: Study of HER2-low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
Abstract Book of ESMO Breast Cancer 2022, Berlin, Germany, 03-05 May 2022   01 mai 2022
Impact of Early Supportive Care Assessment on treatment decision in head and neck cancer before concomitant chemoradiotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   27 avril 2022
Abstract P4-12-05: Benefit of multidisciplinary consultation at initiation of oral antineoplastic agents in metastatic breast cancer patients
2021 San Antonio Breast Cancer Symposium   15 février 2022
117P Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
Abstract Book of the ESMO Breast Cancer Virtual Congress 202105-08 May 2021   01 mai 2021
Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}